Kyverna’s long-term miv-cel readout is being read against a backdrop of safety issues across autoimmune CAR-T peer programs, where investors and regulators are increasingly demanding deeper follow-up. The company’s narrative highlights sustained efficacy coupled with what it called an unblemished safety profile. The message is less about initial responses and more about whether risks remain manageable over time, a key factor for FDA decision-making in one-time cellular therapies. For clinicians, the emphasis is on durability and late adverse-event profiles, which are increasingly decisive when the competitive set is expanding across rare autoimmune disorders.